As such decrease in circulating methylated Rasal1 CpG island promoter fragments in mice correlated with blunted kidney fibrosis upon de-methylating therapy, it is attractive to speculate that decreased levels of methylated RASAL1 DNA fragments and blood pressure-independent attenuation of CKD progression which were observed in patients which had received low-dose Dihydralazine are also reflective of its potential reno-protection. The gene discussed is RASAL1; the disease is chronic kidney disease.